ADMA BIOLOGICS, INC.ADMAEarnings & Financial Report
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Revenue
$134.2M
Gross Profit
$75.6M
Operating Profit
$51.0M
Net Profit
$36.4M
Gross Margin
56.3%
Operating Margin
38.0%
Net Margin
27.1%
YoY Growth
12.0%
EPS
$0.15
ADMA BIOLOGICS, INC. Q3 FY2025 Financial Summary
ADMA BIOLOGICS, INC. reported revenue of $134.2M (up 12.0% YoY) for Q3 FY2025, with a net profit of $36.4M (up 1.4% YoY) (27.1% margin). Cost of goods sold was $58.6M, operating expenses totaled $24.6M.
Key Financial Metrics
| Total Revenue | $134.2M |
|---|---|
| Net Profit | $36.4M |
| Gross Margin | 56.3% |
| Operating Margin | 38.0% |
| Report Period | Q3 FY2025 |
ADMA BIOLOGICS, INC. Annual Revenue by Year
ADMA BIOLOGICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $510.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $510.2M |
| 2024 | $426.5M |
| 2023 | $258.2M |
| 2022 | $154.1M |
ADMA BIOLOGICS, INC. Quarterly Revenue & Net Profit History
ADMA BIOLOGICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $139.2M | +18.4% | $49.4M | 35.5% |
| Q3 FY2025 | $134.2M | +12.0% | $36.4M | 27.1% |
| Q2 FY2025 | $122.0M | +13.8% | $34.2M | 28.1% |
| Q1 FY2025 | $114.8M | +40.2% | $26.9M | 23.4% |
| Q4 FY2024 | $117.5M | +59.1% | $111.9M | 95.2% |
| Q3 FY2024 | $119.8M | +78.1% | $35.9M | 30.0% |
| Q2 FY2024 | $107.2M | +78.3% | $32.1M | 29.9% |
| Q1 FY2024 | $81.9M | +43.9% | $17.8M | 21.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $81.9M | $107.2M | $119.8M | $117.5M | $114.8M | $122.0M | $134.2M | $139.2M |
| YoY Growth | 43.9% | 78.3% | 78.1% | 59.1% | 40.2% | 13.8% | 12.0% | 18.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $350.9M | $376.4M | $390.6M | $488.7M | $510.6M | $558.4M | $568.7M | $624.2M |
| Liabilities | $197.2M | $188.1M | $158.7M | $139.7M | $137.2M | $160.1M | $137.5M | $146.9M |
| Equity | $153.7M | $188.3M | $231.9M | $349.0M | $373.4M | $398.3M | $431.2M | $477.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.2M | $45.6M | $25.0M | $50.2M | $-19.7M | $21.1M | $13.3M | $35.6M |